Home  »  Companies   »  Which Institutions Own Shares In ImmunoGen Inc. (I...

Which Institutions Own Shares In ImmunoGen Inc. (IMGN)?

293 institutions hold shares in ImmunoGen Inc. (IMGN), with 1.03M shares held by insiders accounting for 0.52% while institutional investors hold 89.04% of the company’s shares. The shares outstanding are 187.97M, and float is at 169.84M with Short Float at 12.27%. Institutions hold 88.58% of the Float.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is Wellington Management Group, LLP with over 22.08 million shares valued at $142.44 million. The investor’s holdings represent 11.06% of the IMGN Shares outstanding. As of Dec 30, 2020, the second largest holder is RA Capital Management, L.P. with 18.42 million shares valued at $118.79 million to account for 9.22% of the shares outstanding. The other top investors are Blackrock Inc. which holds 15.16 million shares representing 7.59% and valued at over $97.76 million, while Vanguard Group, Inc. (The) holds 7.09% of the shares totaling 14.16 million with a market value of $91.31 million.

ImmunoGen Inc. (NASDAQ: IMGN) is 24.34% higher on its value in year-to-date trading and has touched a low of $3.38 and a high of $10.88 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The IMGN stock was last observed hovering at around $7.93 in the last trading session, with the day’s gains setting it 0.09% off its average median price target of $10.00 for the next 12 months. It is also 52.82% off the consensus price target high of $17.00 offered by 9 analysts, but current levels are -33.67% lower than the price target low of $6.00 for the same period.

Currently trading at $8.02, the stock is 3.33% and -4.27% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.79 million and changing 1.13% at the moment leaves the stock 29.81% off its SMA200. IMGN registered 103.55% gain for a year compared to 6-month gain of 46.62%. The firm has a 50-day simple moving average (SMA 50) of $8.10 and a 200-day simple moving average (SMA200) of $7.21.

The stock witnessed a -0.50% loss in the last 1 month and extending the period to 3 months gives it a 9.86%, and is 5.80% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.74% over the week and 4.77% over the month.

ImmunoGen Inc. (IMGN) has around 79 employees, a market worth around $1.60B and $132.30M in sales. Profit margin for the company is -33.50%. Distance from 52-week low is 137.28% and -26.29% from its 52-week high. The company has generated returns on investments over the last 12 months (-24.40%).

ImmunoGen Inc. (IMGN) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for ImmunoGen Inc. (IMGN) is a “Overweight”. 9 analysts offering their recommendations for the stock have an average rating of 2.10, where 3 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

ImmunoGen Inc. is expected to release its quarterly report on 07/30/2021 and quarterly earnings per share for the current quarter are estimated at -$0.19 with sales reaching $17.73M over the same period.The EPS is expected to grow by 64.10% this year, but quarterly earnings will post -47.10% year-over-year. Quarterly sales are estimated to grow 33.40% in year-over-year returns.

ImmunoGen Inc. (IMGN) Insider Activity

A total of 6 insider transactions have happened at ImmunoGen Inc. (IMGN) in the last six months, with sales accounting for 2 and purchases happening 4 times. The most recent transaction is an insider sale by FOSTER DAVID G, the company’s V.P.-Fin., Prin. Acctg. Off.. SEC filings show that FOSTER DAVID G sold 11,052 shares of the company’s common stock on Dec 31 at a price of $6.38 per share for a total of $70512.0. Following the sale, the insider now owns 37912.0 shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

ImmunoGen Inc. (IMGN): Who are the competitors?

The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 14.78% up over the past 12 months. Bristol-Myers Squibb Company (BMY) is 6.26% up on the 1-year trading charts. Short interest in the company’s stock has risen 6.59% from the last report on Apr 14, 2021 to stand at a total of 20.84 million short shares sold with a short interest ratio of 11.11.

Related Posts

110500

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam